Most Recent
Bayer wants to amend Xarelto patent at centre of Sandoz’s invalidity claim
German pharmaceutical giant Bayer, which is facing a legal bid by generic drug maker Sandoz to invalidate patents covering blood clot drug Xarelto, is seeking to amend one of the patents in dispute.
In tossing inventor’s IP challenge, Full Court says essential oil a ‘staple commercial product’
The Full Federal Court has rejected an Australian inventor’s appeal of a ruling that found three manufacturers of essential oil products did not infringe his patent because the oil was a “staple commercial product”.
No penalty for IOOF unit RI Advice in ASIC’s novel cybersecurity case
IOOF financial advice unit RI Advice has escaped a penalty in a test case alleging cybersecurity failures, but the firm must engage an IT security company and pay the corporate regulator's legal costs.
IOOF unit settles ASIC’s cybersecurity test case
IOOF unit RI Advice has agreed to settle novel proceedings brought by the Australian Securities and Investments Commission claiming it failed to protect its clients against cybersecurity risks.
Maurice Blackburn prevails in State Street appeal over Fearless Girl
Maurice Blackburn has successfully defeated an appeal of a judgment that found the law firm did not breach the intellectual property rights of US financial services giant State Street Global Advisors by displaying a replica of the world renowned Fearless Girl statue in Melbourne.
Jellycat’s Bashful Bunny plush toy ‘hardly a revolutionary concept’, court told
A toy designer that has been sued for allegedly copying the design of toy maker Jellycat’s beloved ‘Bashful Bunny’ has pushed back at a request for discovery concerning its design process, telling the court “a plush toy in the shape of a bunny is hardly a revolutionary concept”.
Biogen wins discovery for potential IP lawsuit against Sandoz
Swiss pharmaceutical company Biogen has won discovery of documents sent from Sandoz to the Therapeutic Goods Administration, as it weighs a third patent infringement lawsuit to protect its multiple sclerosis drug against generic reproductions.
Biogen may sue third generic drug maker to protect MS drug Tecfidera
Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a drug maker to shield its monopoly in Australia for blockbuster multiple sclerosis drug Tecfidera from generic competition.
Judge slugs Oxymed with $3M penalty for pushing ‘pseudo-scientific’ therapy
An alternative therapies clinic in Victoria has been hit with $3 million in penalties for allegedly promoting “pseudo-scientific” treatments to vulnerable people with chronic illnesses in posts on social media and its website.
Caterpillar resolves case against former employee accused of taking confidential files
Construction equipment giant Caterpillar has resolved its dispute with a former employee accused of flagrantly copying "many thousands" of confidential files before taking a job with a competitor.